Li Shi-Jie, Wu Qi
Endoscopy Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
World J Clin Cases. 2022 Dec 26;10(36):13227-13238. doi: 10.12998/wjcc.v10.i36.13227.
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of mediastinal and hilar lymph is poorly studied in patients with extrathoracic malignancies.
To evaluate the value of EBUS-TBNA for the diagnosis of enlarged intrathoracic lymph nodes in patients with extrathoracic malignancies.
This was a retrospective study of patients with extrathoracic malignancies who were referred to Peking University Cancer Hospital from January 2013 to December 2018 for EBUS-TBNA due to intrathoracic lymphadenopathy. The specimens were defined as positive for malignancy, negative for non-malignancy (tuberculosis, sarcoidosis, ), and without a definitive diagnosis. Sensitivity, negative predictive value (NPV) for malignancy, and overall accuracy were calculated. Complications were recorded.
A total of 80 patients underwent EBUS-TBNA and had a final diagnosis, among which 50 (62.5%) were diagnosed with extrathoracic malignancy with intrathoracic lymph nodes metastasis, 14 (17.5%) were diagnosed with primary lung cancer with nodal involvement, and 16 (20.0%) exhibited benign behavior including tuberculosis, sarcoidosis and reactive lymphadenitis or who had benign follow-up. The diagnostic sensitivity, NPV, and accuracy of EBUS-TBNA for intrathoracic lymphadenopathy in patients with extrathoracic malignancy were 93.8% ( = 60/64), 80.0% ( = 16/20), and 95.0% ( = 76/80), respectively. In the multivariate analysis, longer short axis of the lymph node (OR: 1.200, 95%CI: 1.024-1.407; = 0.024) and synchronous lung lesion (OR: 19.449, 95%CI: 1.875-201.753; = 0.013) were independently associated with malignant intrathoracic lymphadenopathy. No characteristics of the lymph nodes and EBUS-TBNA were associated with the location of malignant intrathoracic lymphadenopathy, and no major complication was observed.
EBUS-TBNA is a simple and accurate procedure for the diagnosis of intrathoracic lymphadenopathy with extrathoracic malignancy.
对于胸外恶性肿瘤患者,经支气管超声引导下经支气管针吸活检术(EBUS-TBNA)用于诊断纵隔和肺门淋巴结的研究较少。
评估EBUS-TBNA对胸外恶性肿瘤患者胸内肿大淋巴结的诊断价值。
这是一项回顾性研究,研究对象为2013年1月至2018年12月因胸内淋巴结肿大转诊至北京大学肿瘤医院接受EBUS-TBNA的胸外恶性肿瘤患者。标本被定义为恶性阳性、非恶性(结核病、结节病等)阴性且未明确诊断。计算敏感性、恶性肿瘤的阴性预测值(NPV)和总体准确率。记录并发症。
共有80例患者接受了EBUS-TBNA并最终确诊,其中50例(62.5%)被诊断为胸外恶性肿瘤伴胸内淋巴结转移,14例(17.5%)被诊断为原发性肺癌伴淋巴结受累,16例(20.0%)表现为良性病变,包括结核病、结节病和反应性淋巴结炎或随访结果为良性。EBUS-TBNA对胸外恶性肿瘤患者胸内淋巴结肿大的诊断敏感性、NPV和准确率分别为93.8%(=60/64)、80.0%(=16/20)和95.0%(=76/80)。在多变量分析中,淋巴结短轴较长(OR:1.200,95%CI:1.024-1.407;=0.024)和同步肺部病变(OR:19.449,95%CI:1.875-201.753;=0.013)与胸内恶性淋巴结病独立相关。淋巴结和EBUS-TBNA的特征与胸内恶性淋巴结病的位置无关,未观察到重大并发症。
EBUS-TBNA是诊断胸外恶性肿瘤伴胸内淋巴结肿大的一种简单、准确的方法。